Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial

V. Gebbia, G. Mantovani, B. Agostara, A. Contu, A. Farris, G. Colucci, F. Cognetti, G. Restivo, R. Speciale, B. Ferrero, A. Testa, L. Curreli, A. Cardinale, E. Bajetta, N. Gebbia

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the head/neck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods: Eighty patients with recurrent and/or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88%). Forty-seven had previously received surgery alone, two radiotherapy alone, and 31 surgery plus radiotherapy. Seventy-two patients had locoregional recurrency, and eight had distant metastases. Results: According to an intent-to-treat analysis, complete response (CR) of a mean duration of 12.7+ months was achieved in 13% of cases (95% CI 5%-21%), and partial response of 8.3+ months in 45% of patients (95% CI 33%-56%), for an overall response rate of 55% (95% CI 43%-65%). Nine patients (11%) showed no change, and 22 (28%) progressed. Five patients were not evaluable for response and toxicity. CR were seen more frequently in patients pretreated with only surgery than in those who had also received radiotherapy (15% vs. 9%, p = 0.7). No statistically significant differences in response rate according to site of primary tumor were found (p = 0.8, NS). The received dose intensities of 5-FU, CDDP, and VNR were 90%, 92%, and 82%, respectively. The overall survival of the series as a whole was 9.7+ months (range 4-27). Toxicity was generally acceptable. Grades 3 and 4 leukopenia were recorded in 11% and 5% of patients, respectively. Noteworthy was the occurrence of pain at the tumor site after vinorelbine administration in 5 patients. Conclusion: The combination regimen of CDDP, 5-FU and vinorelbine is quite active in the treatment of metastatic and/or recurrent SCHNC. This regimen should be tested as initial treatment in previously untreated patients and compared to a standard regimen in recurrent SCHNC.

Original languageEnglish
Pages (from-to)987-991
Number of pages5
JournalAnnals of Oncology
Volume6
Issue number10
Publication statusPublished - 1995

Fingerprint

Cisplatin
Fluorouracil
Radiotherapy
Surgery
Cell
Toxicity
Tumors
Tumor
Therapeutics
Metastasis
Series
Pain
Lung
Carcinoma, squamous cell of head and neck
vinorelbine
Epithelial Cells
Dose
Cavity
Schedule
Partial

Keywords

  • 5-fluorouracil
  • Chemotherapy
  • Cisplatin
  • Head/neck cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil : A multicenter phase II trial. / Gebbia, V.; Mantovani, G.; Agostara, B.; Contu, A.; Farris, A.; Colucci, G.; Cognetti, F.; Restivo, G.; Speciale, R.; Ferrero, B.; Testa, A.; Curreli, L.; Cardinale, A.; Bajetta, E.; Gebbia, N.

In: Annals of Oncology, Vol. 6, No. 10, 1995, p. 987-991.

Research output: Contribution to journalArticle

Gebbia, V, Mantovani, G, Agostara, B, Contu, A, Farris, A, Colucci, G, Cognetti, F, Restivo, G, Speciale, R, Ferrero, B, Testa, A, Curreli, L, Cardinale, A, Bajetta, E & Gebbia, N 1995, 'Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial', Annals of Oncology, vol. 6, no. 10, pp. 987-991.
Gebbia, V. ; Mantovani, G. ; Agostara, B. ; Contu, A. ; Farris, A. ; Colucci, G. ; Cognetti, F. ; Restivo, G. ; Speciale, R. ; Ferrero, B. ; Testa, A. ; Curreli, L. ; Cardinale, A. ; Bajetta, E. ; Gebbia, N. / Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil : A multicenter phase II trial. In: Annals of Oncology. 1995 ; Vol. 6, No. 10. pp. 987-991.
@article{c4495df4746d4958a564cadb28212f67,
title = "Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial",
abstract = "Purpose: Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the head/neck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods: Eighty patients with recurrent and/or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88{\%}). Forty-seven had previously received surgery alone, two radiotherapy alone, and 31 surgery plus radiotherapy. Seventy-two patients had locoregional recurrency, and eight had distant metastases. Results: According to an intent-to-treat analysis, complete response (CR) of a mean duration of 12.7+ months was achieved in 13{\%} of cases (95{\%} CI 5{\%}-21{\%}), and partial response of 8.3+ months in 45{\%} of patients (95{\%} CI 33{\%}-56{\%}), for an overall response rate of 55{\%} (95{\%} CI 43{\%}-65{\%}). Nine patients (11{\%}) showed no change, and 22 (28{\%}) progressed. Five patients were not evaluable for response and toxicity. CR were seen more frequently in patients pretreated with only surgery than in those who had also received radiotherapy (15{\%} vs. 9{\%}, p = 0.7). No statistically significant differences in response rate according to site of primary tumor were found (p = 0.8, NS). The received dose intensities of 5-FU, CDDP, and VNR were 90{\%}, 92{\%}, and 82{\%}, respectively. The overall survival of the series as a whole was 9.7+ months (range 4-27). Toxicity was generally acceptable. Grades 3 and 4 leukopenia were recorded in 11{\%} and 5{\%} of patients, respectively. Noteworthy was the occurrence of pain at the tumor site after vinorelbine administration in 5 patients. Conclusion: The combination regimen of CDDP, 5-FU and vinorelbine is quite active in the treatment of metastatic and/or recurrent SCHNC. This regimen should be tested as initial treatment in previously untreated patients and compared to a standard regimen in recurrent SCHNC.",
keywords = "5-fluorouracil, Chemotherapy, Cisplatin, Head/neck cancer, Vinorelbine",
author = "V. Gebbia and G. Mantovani and B. Agostara and A. Contu and A. Farris and G. Colucci and F. Cognetti and G. Restivo and R. Speciale and B. Ferrero and A. Testa and L. Curreli and A. Cardinale and E. Bajetta and N. Gebbia",
year = "1995",
language = "English",
volume = "6",
pages = "987--991",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil

T2 - A multicenter phase II trial

AU - Gebbia, V.

AU - Mantovani, G.

AU - Agostara, B.

AU - Contu, A.

AU - Farris, A.

AU - Colucci, G.

AU - Cognetti, F.

AU - Restivo, G.

AU - Speciale, R.

AU - Ferrero, B.

AU - Testa, A.

AU - Curreli, L.

AU - Cardinale, A.

AU - Bajetta, E.

AU - Gebbia, N.

PY - 1995

Y1 - 1995

N2 - Purpose: Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the head/neck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods: Eighty patients with recurrent and/or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88%). Forty-seven had previously received surgery alone, two radiotherapy alone, and 31 surgery plus radiotherapy. Seventy-two patients had locoregional recurrency, and eight had distant metastases. Results: According to an intent-to-treat analysis, complete response (CR) of a mean duration of 12.7+ months was achieved in 13% of cases (95% CI 5%-21%), and partial response of 8.3+ months in 45% of patients (95% CI 33%-56%), for an overall response rate of 55% (95% CI 43%-65%). Nine patients (11%) showed no change, and 22 (28%) progressed. Five patients were not evaluable for response and toxicity. CR were seen more frequently in patients pretreated with only surgery than in those who had also received radiotherapy (15% vs. 9%, p = 0.7). No statistically significant differences in response rate according to site of primary tumor were found (p = 0.8, NS). The received dose intensities of 5-FU, CDDP, and VNR were 90%, 92%, and 82%, respectively. The overall survival of the series as a whole was 9.7+ months (range 4-27). Toxicity was generally acceptable. Grades 3 and 4 leukopenia were recorded in 11% and 5% of patients, respectively. Noteworthy was the occurrence of pain at the tumor site after vinorelbine administration in 5 patients. Conclusion: The combination regimen of CDDP, 5-FU and vinorelbine is quite active in the treatment of metastatic and/or recurrent SCHNC. This regimen should be tested as initial treatment in previously untreated patients and compared to a standard regimen in recurrent SCHNC.

AB - Purpose: Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the head/neck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods: Eighty patients with recurrent and/or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88%). Forty-seven had previously received surgery alone, two radiotherapy alone, and 31 surgery plus radiotherapy. Seventy-two patients had locoregional recurrency, and eight had distant metastases. Results: According to an intent-to-treat analysis, complete response (CR) of a mean duration of 12.7+ months was achieved in 13% of cases (95% CI 5%-21%), and partial response of 8.3+ months in 45% of patients (95% CI 33%-56%), for an overall response rate of 55% (95% CI 43%-65%). Nine patients (11%) showed no change, and 22 (28%) progressed. Five patients were not evaluable for response and toxicity. CR were seen more frequently in patients pretreated with only surgery than in those who had also received radiotherapy (15% vs. 9%, p = 0.7). No statistically significant differences in response rate according to site of primary tumor were found (p = 0.8, NS). The received dose intensities of 5-FU, CDDP, and VNR were 90%, 92%, and 82%, respectively. The overall survival of the series as a whole was 9.7+ months (range 4-27). Toxicity was generally acceptable. Grades 3 and 4 leukopenia were recorded in 11% and 5% of patients, respectively. Noteworthy was the occurrence of pain at the tumor site after vinorelbine administration in 5 patients. Conclusion: The combination regimen of CDDP, 5-FU and vinorelbine is quite active in the treatment of metastatic and/or recurrent SCHNC. This regimen should be tested as initial treatment in previously untreated patients and compared to a standard regimen in recurrent SCHNC.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Cisplatin

KW - Head/neck cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0029591358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029591358&partnerID=8YFLogxK

M3 - Article

C2 - 8750150

AN - SCOPUS:0029591358

VL - 6

SP - 987

EP - 991

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -